Biopharmconsortium Blog

Expert commentary from Haberman Associates biotechnology and pharmaceutical consulting.

Monthly Archives: August 2012

Here we go again–Lilly’s Alzheimer’s drug solanezumab fails to show efficacy in Phase 3, but company is “encouraged” by secondary analysis

Tweet  As we mentioned in our August 19, 2012 article on Alzheimer’s disease (AD), the results of Phase 3 trials of Lilly‚Äôs amyloid-targeting monoclonal antibody (MAb) drug solanezumab, had been expected soon. On August 24 2012, Lilly announced the top-line results of the two Phase 3, double-blind, placebo-controlled EXPEDITION trials of solanezumab in patients with…

New genetics study supports the amyloid hypothesis of Alzheimer’s disease–but the drugs still don’t work!

Tweet  An exciting new study on Alzheimer’s disease (AD) was published in the 2 August issue of Nature. The study was carried out by researchers at deCode Genetics (Reykjavik Iceland) and their collaborators at Genentech and several academic institutions. A News and Views article by leading AD researcher Bart De Strooper and genomics researcher Thierry…

Beige fat enters the obesity-therapeutics target arena

Tweet  This is an update to our recent discussion on targeting the physiology of brown fat [or brown adipose tissue (BAT)], in developing novel antiobesity therapies. It is based on a research article published in the July 20 2012 issue of Cell by Dr. Bruce Spiegelman (Dana-Farber Cancer Institute and Harvard Medical School, Boston MA)…

Announcing the 2nd Annual Partnership Opportunities in Drug Delivery Conference: 10/1-10/2/2012

Tweet2nd Annual Partnership Opportunities in Drug Delivery October 1st and 2nd 2012 The Boston Park Plaza Hotel & Towers 50 Park Plaza at Arlington Street Boston, MA, 02116-3912 Keynoted by Dr Robert Langer of MIT, this is a strategic level event designed with two purposes: 1. To present a strategic level event for pharma and…